Repeat pull from proven relationships plus room left: the installed base is expanding on its own initiative and is still
The model's full reasoning — Q1 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe that counterparties the company has ALREADY SERVED AND PROVEN ITSELF WITH — existing customers, accounts, partners, members, or programs — are CURRENTLY, ON THEIR OWN INITIATIVE, TAKING OR COMMITTING TO MEANINGFULLY MORE from the company than they previously did (larger or earlier reorders, broader deployments, added sites, products, or scope, relationships stepped up to bigger phases), AND does management convey that these same relationships remain LIGHTLY PENETRATED — that what these counterparties have taken so far is still a small share of what they could take — so that the expansion now visible is early? We need to look for evidence in the transcript. The company is Curis, a biotech. They have programs: CUDC-907, CA170, and Erivedge (partnered with Genentech/Roche). The question is about existing relationships expanding. For example, Genentech/Roche are partners for Erivedge. Management mentions that Roche has initiated two clinical studies with Erivedge outside of BCC (basal cell carcinoma) - one in myelofibrosis and one in IPF. That is an expansion of the use of Erivedge into new indications. That is a partner (Roche) taking more from the company (expanding the scope of the drug). Also, the company's own programs: CUDC-907 is moving from Phase 1 to Phase 2, but that's not a counterparty relationship. CA170 is entering clinic. The question specifically asks about counterparties (existing customers, accounts, partners, members, programs) that have already been served and proven themselves. The only clear partner is Genentech/Roche for Erivedge. Management says: "We are pleased to note that Roche has initiated enrollment in two clinical studies with Erivedge outside of BCC. One study in patients with intermediate or high risk myelofibrosis where Erivedge is being studied in combination with ruxolitinib, a JAK inhibitor and a second study in idiopathic pulmonary fibrosis patients or IPF where Erivedge is being investigated in combination with pirfenidone, the standard of care for these patients." That is Roche, the partner, taking Erivedge into new indications, which is a broader deployment. That is an expansion of the relationship. Is it "on their own initiative"? It seems Roche is doing these studies. Management is reporting it.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
ZVIA · Q1 2022 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES Management describes existing customers (households and Club channel buyers) already taking meaningfully more through velocity (51% of growth), higher buy rates (+9%), and heavier consumption in the food channel, while conveying that these relationships remain lightly penetrated with substantial room ahead (new households, expanded flavors, broader deployments). This is 100% present-tense, driven by counterparties’ own choice after direct experience, not price hikes or auto-renewal, and the expansion is already occurring across multiple accounts rather than isolated or projected.
PI · Q4 2022 → YESThe question is about whether management describes existing customers expanding their business with the company, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing customers expanding through program expansions, broader deployments, and continued system deployments that are already occurring and expected to drive large volumes in 2023 and beyond, while conveying that these relationships remain lightly penetrated with substantial room for further growth in scope, sites, and usage.
CVS · Q1 2018 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing partnerships (Optum and Cigna clients) already taking more programs through an uptick in CVS Pharmacy and MinuteClinic offerings, driven by the companies' own adoption after experience, with continued opportunities for 2020 and beyond indicating substantial room remains in those relationships.